On Monday, Wells Fargo (NYSE:WFC) issued a downgrade for HCA Healthcare Inc (NYSE:NYSE:HCA) stock, shifting the rating from Equal Weight to Underweight. This adjustment comes with a significant reduction in the price target for the healthcare company's shares, now set at $320.00, down from the previous target of $400.00.
The decision to downgrade HCA Healthcare's stock was based on a detailed analysis of the company's financial prospects. Wells Fargo's revised price target is rooted in an 8.75 times multiple of their 2026 adjusted EBITDA Less NCI estimate, which is projected to be $13.9 billion. Additionally, the target is aligned with the company's balance sheet as of December 31, 2025.
Wells Fargo's methodology for setting the new price target involved a comparison with historical valuation multiples for HCA Healthcare. The target multiple represents a mixed adjustment in relation to the company's average multiples over the past three, five, and ten years. Specifically, it includes a 0.5 times reduction, a 0.2 times reduction, and a 0.2 times premium, respectively.
This reevaluation of HCA Healthcare's stock reflects Wells Fargo's current outlook on the company's financial performance, considering both historical data and future projections. The new target multiple aims to provide a balanced view by incorporating both discounts and premiums against the averages of different timeframes.
Investors and market watchers are now equipped with Wells Fargo's latest perspective on HCA Healthcare. The new underweight rating and adjusted price target are indicators of the financial institution's expectations for the healthcare provider's stock performance in the coming years.
In other recent news, HCA Healthcare reported a 25% increase in adjusted diluted earnings per share to $4.90 and a 7.1% revenue growth from the same facilities, despite challenges posed by Hurricanes Helene and Milton leading to an estimated revenue loss of $50 million for Q3 and an additional projected loss of $200-$300 million for Q4.
The company also announced expansion plans, aiming to add 600 inpatient beds and 100 outpatient facilities by the end of 2024 and anticipates volume growth between 3% to 4% for 2025. Analyst firms Oppenheimer, KeyBanc Capital Markets, TD Cowen, Mizuho (NYSE:MFG), and Cantor Fitzgerald have adjusted their price targets and ratings for HCA Healthcare following these developments.
Oppenheimer raised its price target to $400, maintaining an Outperform rating, while KeyBanc reduced its target to $420, TD Cowen adjusted its target to $440, Mizuho maintained its target at $425, and Cantor Fitzgerald raised its target to $405. These adjustments reflect the recent performance and future expectations of HCA Healthcare as analyzed by these firms.
InvestingPro Insights
To complement Wells Fargo's analysis, InvestingPro data offers additional insights into HCA Healthcare's financial position. As of the last twelve months ending Q3 2024, HCA reported a robust revenue of $69.62 billion, with a healthy revenue growth of 10.23%. The company's profitability is evident from its adjusted operating income of $10.5 billion and an operating income margin of 15.08%.
InvestingPro Tips highlight that HCA has been aggressively buying back shares, which could potentially support the stock price. Additionally, the company has raised its dividend for 4 consecutive years, demonstrating a commitment to shareholder returns. This is further supported by a dividend yield of 0.81% and a dividend growth of 10% over the last twelve months.
While Wells Fargo has downgraded the stock, it's worth noting that HCA's P/E ratio stands at 14.35, which may be considered attractive by some investors. Moreover, an InvestingPro Tip suggests that the stock's valuation implies a strong free cash flow yield, which could be of interest to value-oriented investors.
For readers seeking a more comprehensive analysis, InvestingPro offers 12 additional tips on HCA Healthcare, providing a broader perspective on the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.